Steven Foung
Publications
- Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. J Virol. 2013; (3): 1385-99
- Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. J Virol. 2013; (8): 4214-24
- Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol. 2013; (1): 37-51
- Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog. 2013; (5): e1003364
- Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 2012; (4): e1002653
- Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology. 2012; (1): 223-233.e9
- Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody. J Virol. 2012; (23): 12923-32
- Transient activation of the PI3K-AKT pathway by hepatitis C virus to enhance viral entry. J Biol Chem. 2012; (50): 41922-30
- Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem. 2011; (51): 44218-33
- Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J Gen Virol. 2011; (Pt 10): 2249-61
- Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virions. Int J Hepatol. 2011: 968161
- Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol. 2011; (20): 10451-63
- Neutralizing antibody response to hepatitis C virus. Viruses. 2011; (11): 2127-45
- The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol. 2011; (Pt 2): 233-46
- The hepatitis C virus E1 glycoprotein undergoes productive folding but accelerated degradation when expressed as an individual subunit in CHO cells. PLoS One. 2011; (8): e23838
- Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol. 2010; (11): 5751-63
- Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol. 2010; (11): 5494-507
- Antigen-specific proteolysis by hybrid antibodies containing promiscuous proteolytic light chains paired with an antigen-binding heavy chain. J Biol Chem. 2009; (36): 24622-33
- CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol. 2009; (Pt 1): 48-58
- A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope. J Virol. 2008; (12): 6067-72
- Antibody-dependent enhancement of hepatitis C virus infection. J Virol. 2008; (5): 2140-9
- Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol. 2008; (Pt 3): 653-9
- Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol. 2008; (12): 6061-6
- Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J Virol. 2008; (13): 6711-20
- In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A. 2008; (49): 19450-5
- Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoprotein. Biochim Biophys Acta. 2008; (3): 530-42
- Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr Top Microbiol Immunol. 2008: 1-38
- Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol. 2007; (2): 1043-7
- The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol. 2007; (15): 8101-11
- Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol. 2006; (2): 866-74
- High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem. 2006; (27): 18285-95
- Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol. 2006; (6): 2654-64
- Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol. 2005; (21): 13199-208
- Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology. 2005; (1): 438-53
- Antibody light chain-catalyzed hydrolysis of a hepatitis C virus peptide. Bioorg Med Chem Lett. 2004; (17): 4529-32
- Characterization of functional hepatitis C virus envelope glycoproteins. J Virol. 2004; (6): 2994-3002
- Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol. 2004; (17): 9224-32
- Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol. 2004; (13): 7257-63
- Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein. J Immunol. 2004; (1): 446-55
- DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem. 2003; (22): 20358-66
- Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol. 2003; (2): 1604-9
- Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras. AIDS Res Hum Retroviruses. 2002; (1): 57-70
- Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology. 2002; (1): 124-32
- Cross-reactivity and clinical impact of the antibody response to hepatitis C virus second envelope glycoprotein (E2). J Med Virol. 2001; (1): 23-9
- The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood. 2001; (13): 3745-9
- V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood. 2001; (4): 1023-6
- Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol. 2000; (22): 10407-16
- The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes. J Virol. 1999; (2): 1205-12
- Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia. Br J Haematol. 1998; (2): 318-24
- Experimental infection of chimpanzees with hepatitis G virus and genetic analysis of the virus. J Infect Dis. 1998; (4): 855-62
- GBV-C/HGV: a new virus within the Flaviviridae and its clinical implications. Transfus Med Rev. 1998; (2): 94-108
- Large granular lymphocyte leukaemia occurring after renal transplantation. Br J Haematol. 1998; (3): 507-12
- Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46. J Virol. 1997; (8): 5828-40
- Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes. Blood. 1997; (5): 1977-81
- A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system. J Virol. 1996; (11): 7349-59
- Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science. 1996; (5248): 505-8
- Delineation of an immunodominant and human T-cell lymphotropic virus (HTLV)-specific epitope within the HTLV-I transmembrane glycoprotein. Blood. 1995; (4): 1392-9
- Enhanced specificity of truncated transmembrane protein for serologic confirmation of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infections by western blot (immunoblot) assay containing recombinant envelope glycoproteins. J Clin Microbiol. 1995; (12): 3239-44
- Stabilizing antibody secretion of human Epstein Barr virus-activated B-lymphocytes with hybridoma formation by electrofusion. Methods Mol Biol. 1995: 295-307
- Immunoglobulin prophylaxis against human T cell lymphotropic virus type II in rabbits. J Infect Dis. 1994; (3): 620-3
- Localization of antigenic sites on human cytomegalovirus virion structural proteins encoded by UL48 and UL56. Virology. 1994; (1): 321-8
- Amplification and detection of a single molecule of human immunodeficiency virus RNA. Virus Genes. 1993; (4): 325-38
- Association of '(tropical) ataxic neuropathy' with HTLV-II. Virus Res. 1993; (1): 71-7
- Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus types I and II. J Clin Microbiol. 1993; (2): 260-4
- Human T lymphotropic virus type I/II in Lake Lindu Valley, Central Sulawesi, Indonesia. J Acquir Immune Defic Syndr. 1993; (9): 1067-8
- Isotypic and IgG subclass restriction of the humoral immune responses to human T-lymphotropic virus type-I. Clin Immunol Immunopathol. 1993; (1): 40-9
- Neutralizing antibody to vesicular stomatitis virus (HTLV-I) pseudotype in infants born to seropositive mothers. Jpn J Cancer Res. 1993; (2): 114-6
- Spastic ataxia associated with human T-cell lymphotropic virus type II infection. Ann Neurol. 1993; (4): 411-4
- Cloning and analysis of a recombinant antigen containing an epitope specific for human T-cell lymphotropic virus type II. Blood. 1992; (10): 2789-96
- Immune responsiveness to the immunodominant recombinant envelope epitopes of human T lymphotropic virus types I and II in diverse geographic populations. J Infect Dis. 1992; (5): 1160-3
- Serologic confirmation of simian T-lymphotropic virus type I infection by using immunoassays developed for human T-lymphotropic virus antibody detection. J Clin Microbiol. 1992; (4): 858-61
- Antibodies to hepatitis C virus in low-risk blood donors: implications for counseling positive donors. Gastroenterology. 1991; (6): 1724-7
- HTLV-I-associated myelopathy in a Californian: diagnosis by reactivity to a viral recombinant antigen. Neurology. 1991; (3): 448-50
- Modified Western blot assay for confirmation and differentiation of human T cell lymphotropic virus types I and II. J Infect Dis. 1991; (2): 400-3
- Parameters to enhance human hybridoma formation with hypoosmolar electrofusion. Hum Antibodies Hybridomas. 1991; (3): 155-9
- Significance of human T-lymphotropic virus type I indeterminant serological findings among healthy individuals. Vox Sang. 1991; (3): 171-6
- Low incidence of HTLV infections in random blood donors with indeterminate western blot patterns. Transfusion. 1990 Jul-Aug; (6): 491-4
- Development of microfusion techniques to generate human hybridomas. J Immunol Methods. 1990; (1): 35-42
- Efficient hybridization of mouse-human cell lines by means of hypo-osmolar electrofusion. J Immunol Methods. 1990; (1): 43-50
- Generation of a human hybridoma producing a pure anti-HLA-A2 monoclonal antibody. Hum Immunol. 1990; (1): 65-9
- Electric field-induced cell fusion and human monoclonal antibodies. J Immunol Methods. 1989; (1): 117-22
- Human monoclonal antibodies to human cytomegalovirus. J Infect Dis. 1989; (3): 436-43
- Initial identification and mapping of distinct Rh0 (D) epitopes. Rev Fr Transfus Immunohematol. 1988; (2): 223-31
- The efficacy of PlA1-negative platelet transfusion therapy in posttransfusion purpura. West J Med. 1988; (1): 86-8
- Human monoclonal anti-T cell antibody from a patient with juvenile rheumatoid arthritis. J Immunol. 1987; (1): 104-8
- Human monoclonal antibodies to Rh0(D). Vox Sang. 1987; (1): 44-7
- A human monoclonal antibody to rhG. Vox Sang. 1986; (3): 160-3
- A monoclonal antibody against HLA-A11 and A24. Hum Immunol. 1986; (3): 316-9
- Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis. 1986; (3): 422-9
- Generation of human monoclonal antibodies by fusion of EBV-activated B cells to a human-mouse hybridoma. Methods Enzymol. 1986: 168-74
- A new approach to the diagnosis of active Rh0(D) immunization in passively immunized pregnant women. Vox Sang. 1985; (3): 206-10
- Human monoclonal antibodies against group A red blood cells. Vox Sang. 1985; (5): 305-8
- Human monoclonal antibodies neutralizing varicella-zoster virus. J Infect Dis. 1985; (2): 280-5
- Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J Immunol Methods. 1984; (1): 83-90
- Monoclonal antibody (B27M2) subdividing HLA-B27. Hum Immunol. 1982; (1): 61-72
- Production of functional human T-T hybridomas in selection medium lacking aminopterin and thymidine. Proc Natl Acad Sci U S A. 1982; (23): 7484-8
- Eosinophilia in children. Pediatr Ann. 1979; (6): 39-51
- The effects of starvation and refeeding on muscle protein synthesis and catabolism in the young rat. J Nutr. 1978; (5): 759-65
Help
Trial Administration